222 related articles for article (PubMed ID: 38568691)
1. Public Health Interventions and Overdose-Related Outcomes Among Persons With Opioid Use Disorder.
Nataraj N; Rikard SM; Zhang K; Jiang X; Guy GP; Rice K; Mattson CL; Gladden RM; Mustaquim DM; Illg ZN; Seth P; Noonan RK; Losby JL
JAMA Netw Open; 2024 Apr; 7(4):e244617. PubMed ID: 38568691
[TBL] [Abstract][Full Text] [Related]
2. Estimated Reductions in Opioid Overdose Deaths With Sustainment of Public Health Interventions in 4 US States.
Chhatwal J; Mueller PP; Chen Q; Kulkarni N; Adee M; Zarkin G; LaRochelle MR; Knudsen AB; Barbosa C
JAMA Netw Open; 2023 Jun; 6(6):e2314925. PubMed ID: 37294571
[TBL] [Abstract][Full Text] [Related]
3. Association of Receipt of Opioid Use Disorder-Related Telehealth Services and Medications for Opioid Use Disorder With Fatal Drug Overdoses Among Medicare Beneficiaries Before and During the COVID-19 Pandemic.
Jones CM; Shoff C; Blanco C; Losby JL; Ling SM; Compton WM
JAMA Psychiatry; 2023 May; 80(5):508-514. PubMed ID: 36988913
[TBL] [Abstract][Full Text] [Related]
4. Modeling Mitigation Strategies to Reduce Opioid-Related Morbidity and Mortality in the US.
Ballreich J; Mansour O; Hu E; Chingcuanco F; Pollack HA; Dowdy DW; Alexander GC
JAMA Netw Open; 2020 Nov; 3(11):e2023677. PubMed ID: 33146732
[TBL] [Abstract][Full Text] [Related]
5. The impact of the implementation of medication for opioid use disorder and COVID-19 in a statewide correctional system on treatment engagement, postrelease continuation of care, and overdose.
Klemperer EM; Wreschnig L; Crocker A; King-Mohr J; Ramniceanu A; Brooklyn JR; Peck KR; Rawson RA; Evans EA
J Subst Use Addict Treat; 2023 Sep; 152():209103. PubMed ID: 37311520
[TBL] [Abstract][Full Text] [Related]
6. Projected Estimates of Opioid Mortality After Community-Level Interventions.
Linas BP; Savinkina A; Madushani RWMA; Wang J; Eftekhari Yazdi G; Chatterjee A; Walley AY; Morgan JR; Epstein RL; Assoumou SA; Murphy SM; Schackman BR; Chrysanthopoulou SA; White LF; Barocas JA
JAMA Netw Open; 2021 Feb; 4(2):e2037259. PubMed ID: 33587136
[TBL] [Abstract][Full Text] [Related]
7. Estimated Costs and Outcomes Associated With Use and Nonuse of Medications for Opioid Use Disorder During Incarceration and at Release in Massachusetts.
Chatterjee A; Weitz M; Savinkina A; Macmadu A; Madushani RWMA; Potee RA; Ryan D; Murphy SM; Walley AY; Linas BP
JAMA Netw Open; 2023 Apr; 6(4):e237036. PubMed ID: 37058306
[TBL] [Abstract][Full Text] [Related]
8. Examining buprenorphine diversion through a harm reduction lens: an agent-based modeling study.
Adams JW; Duprey M; Khan S; Cance J; Rice DP; Bobashev G
Harm Reduct J; 2023 Oct; 20(1):150. PubMed ID: 37848945
[TBL] [Abstract][Full Text] [Related]
9. Effect of reductions in opioid prescribing on opioid use disorder and fatal overdose in the United States: a dynamic Markov model.
Alexander GC; Ballreich J; Mansour O; Dowdy DW
Addiction; 2022 Apr; 117(4):969-976. PubMed ID: 34590369
[TBL] [Abstract][Full Text] [Related]
10. Trends in opioid use disorder and overdose among opioid-naive individuals receiving an opioid prescription in Massachusetts from 2011 to 2014.
Burke LG; Zhou X; Boyle KL; Orav EJ; Bernson D; Hood ME; Land T; Bharel M; Frakt AB
Addiction; 2020 Mar; 115(3):493-504. PubMed ID: 31691390
[TBL] [Abstract][Full Text] [Related]
11. Association between treatment setting and outcomes among oregon medicaid patients with opioid use disorder: a retrospective cohort study.
Hartung DM; Markwardt S; Johnston K; Geddes J; Baker R; Leichtling G; Hildebran C; Chan B; Cook RR; McCarty D; Ghitza U; Korthuis PT
Addict Sci Clin Pract; 2022 Aug; 17(1):45. PubMed ID: 35986384
[TBL] [Abstract][Full Text] [Related]
12. Receipt of Telehealth Services, Receipt and Retention of Medications for Opioid Use Disorder, and Medically Treated Overdose Among Medicare Beneficiaries Before and During the COVID-19 Pandemic.
Jones CM; Shoff C; Hodges K; Blanco C; Losby JL; Ling SM; Compton WM
JAMA Psychiatry; 2022 Oct; 79(10):981-992. PubMed ID: 36044198
[TBL] [Abstract][Full Text] [Related]
13. "They make it too hard and too many hoops to jump": system and organizational barriers to drug treatment during epidemic rates of opioid overdose.
Dickson-Gomez J; Krechel S; Ohlrich J; Montaque HDG; Weeks M; Li J; Havens J; Spector A
Harm Reduct J; 2024 Feb; 21(1):52. PubMed ID: 38413972
[TBL] [Abstract][Full Text] [Related]
14. Association of Opioid Dose Reduction With Opioid Overdose and Opioid Use Disorder Among Patients Receiving High-Dose, Long-term Opioid Therapy in North Carolina.
DiPrete BL; Ranapurwala SI; Maierhofer CN; Fulcher N; Chelminski PR; Ringwalt CL; Ives TJ; Dasgupta N; Go VF; Pence BW
JAMA Netw Open; 2022 Apr; 5(4):e229191. PubMed ID: 35476064
[TBL] [Abstract][Full Text] [Related]
15. Association of medications for opioid use disorder with reduced risk of repeat opioid overdose in Medicaid: A cohort study.
Tipping AD; Nowels M; Moore C; Samples H; Crystal S; Olfson M; Williams AR; Heaps-Woodruff J
J Subst Use Addict Treat; 2024 Feb; 157():209218. PubMed ID: 37984564
[TBL] [Abstract][Full Text] [Related]
16. High-deductible Health Plans and Nonfatal Opioid Overdose.
Eddelbuettel JCP; Barry CL; Kennedy-Hendricks A; Busch AB; Hollander MAG; Huskamp HA; Meiselbach MK; Schilling C; Stuart EA; Eisenberg MD
Med Care; 2023 Sep; 61(9):601-604. PubMed ID: 37449857
[TBL] [Abstract][Full Text] [Related]
17. Follow-up after ED visits for opioid use disorder: Do they reduce future overdoses?
Medicaid Outcomes Distributed Research Network
J Subst Abuse Treat; 2022 Nov; 142():108807. PubMed ID: 35649885
[TBL] [Abstract][Full Text] [Related]
18. Prescription-related risk factors for opioid-related overdoses in the era of fentanyl contamination of illicit drug supply: A retrospective case-control study.
Smolina K; Crabtree A; Chong M; Park M; Mill C; Zhao B; Schütz CG
Subst Abus; 2022; 43(1):92-98. PubMed ID: 32441588
[No Abstract] [Full Text] [Related]
19. Population-level impact of initiating pharmacotherapy and linking to care people with opioid use disorder at inpatient medically managed withdrawal programs: an effectiveness and cost-effectiveness analysis.
Savinkina A; Madushani RWMA; Eftekhari Yazdi G; Wang J; Barocas JA; Morgan JR; Assoumou SA; Walley AY; Linas BP; Murphy SM
Addiction; 2022 Sep; 117(9):2450-2461. PubMed ID: 35315162
[TBL] [Abstract][Full Text] [Related]
20. Developing a cascade of care for opioid use disorder among individuals in jail.
Ray B; Victor G; Cason R; Hamameh N; Kubiak S; Zettner C; Dunnigan M; Comartin E; Costello M
J Subst Abuse Treat; 2022 Jul; 138():108751. PubMed ID: 35241352
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
